Pear Therapeutics (US)

Press Releases

Pear Therapeutics to Present at Canaccord Genuity 38th Annual Growth Conference

Boston, July 31, 2018 – Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that Corey McCann, M.D., Ph.D., President and CEO, will present at the Canaccord Genuity 38th Annual Growth Conference on Thursday, August 9th at 10:30 a.m. at the InterContinental Boston.

Pear Therapeutics is a privately held prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious medical conditions.

About Pear Therapeutics

At Pear, our mission is clear: we are pioneers in Prescription Digital Therapeutics, or PDTs. Our cross-functional team operates at the intersection of biotechnology and software technology. Pear discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine. Pear has a pipeline of products and product candidates across therapeutic areas, including mental health disorders, severe insomnia and multiple sclerosis. Our lead product, reSET®, treats Substance Use Disorder, and was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product candidate, reSET-O™ for the treatment of Opioid Use Disorder, is currently under review by the FDA with Breakthrough Designation. For more information, visit us at


Media and Investors:
Amanda Galgay